| Catalog No. | DF879028 |
|---|
| Sample type | Plasma, Serum |
|---|
| Sensitivity | 329.66 ng/mL |
|---|
| Range | 468.75 - 30, 000 ng/mL |
|---|
| Accession |
P01375 |
| Applications |
ELISA |
| Detection method |
Colorimetric |
| Assay type |
Quantitative |
| Recovery |
80-120% |
| Shipping |
2-8 ℃ |
| Stability and Storage |
When the kit was stored at the recommended temperature for 6 months, the signal intensity decreased by less than 20%. For unopened kits, if you want to prolong the storage time, please store the Standard, Detection A, Detection B and Microplate at - 20 ℃, the rest reagents should be store at 4℃. |
| Specifications |
Certolizumab
|
| Alternate Names | CDP870, PHA-738144, Certolizumab pegol, 428863-50-7 |
|---|
| Background | Certolizumab pegol is a recombinant, humanized F(ab)’ fragment of an antibody conjugated to polyethylene glycol to enhance its plasma half-life. It does not contain an FC region and therefore does not cause antibody-dependent cell-mediated or complement-dependent cytotoxicity as described for infliximab, etanercept, and adalimumab. Another difference is that certolizumab pegol preferentially penetrates inflamed tissue compared to noninflamed tissue, and does so to a greater extent than adalimumab or infliximab. It is directed against soluble and membrane-associated human TNF-α and was approved for the treatment of Crohn’s disease that does not respond to conventional therapy in 2008 and for RA in 2009. |
|---|
| Note |
For Research Use Only. |
